Modality
siRNA
MOA
CGRPant
Target
CDK4/6
Pathway
Tau
Urothelial Ca
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
~Aug 2017
→ ~Nov 2018
Phase 2
Feb 2019
→ Jan 2029
Phase 2Current
NCT04998296
1,496 pts·Urothelial Ca
2024-02→2029-01·Active
NCT06518112
2,518 pts·Urothelial Ca
2019-02→2025-10·Active
4,014 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-195mo agoPh2 Data· Urothelial Ca
2029-01-022.8y awayPh2 Data· Urothelial Ca
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P2
Active
P2
Active
Catalysts
Ph2 Data
2025-10-19 · 5mo ago
Urothelial Ca
Ph2 Data
2029-01-02 · 2.8y away
Urothelial Ca
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04998296 | Phase 2 | Urothelial Ca | Active | 1496 | 6MWD |
| NCT06518112 | Phase 2 | Urothelial Ca | Active | 2518 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF |